XNAS
MDWD
Market cap233mUSD
Jun 09, Last price
21.46USD
1D
-0.65%
1Q
24.69%
Jan 2017
-33.05%
IPO
-83.12%
Name
Mediwound Ltd
Chart & Performance
Profile
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 20,222 8.22% | 18,686 -29.48% | 26,496 11.50% | |||||||
Cost of revenue | 39,376 | 33,952 | 33,883 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (19,154) | (15,266) | (7,387) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 61 | 185 | 78 | |||||||
Tax Rate | ||||||||||
NOPAT | (19,215) | (15,451) | (7,465) | |||||||
Net income | (30,224) 350.03% | (6,716) -65.73% | (19,599) 44.63% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 22,165 | 24,909 | 38,380 | |||||||
BB yield | -12.50% | -27.17% | -57.05% | |||||||
Debt | ||||||||||
Debt current | 532 | |||||||||
Long-term debt | 13,026 | 12,700 | 1,692 | |||||||
Deferred revenue | 736 | |||||||||
Other long-term liabilities | 8,553 | 17,685 | 26,199 | |||||||
Net debt | 3,871 | (29,331) | (32,035) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (13,624) | (10,465) | (11,885) | |||||||
CAPEX | (6,273) | (6,464) | (555) | |||||||
Cash from investing activities | (8,397) | (34,321) | (481) | |||||||
Cash from financing activities | 19,394 | 22,917 | 35,764 | |||||||
FCF | (40,551) | (17,851) | (16,965) | |||||||
Balance | ||||||||||
Cash | 9,155 | 41,541 | 33,895 | |||||||
Long term investments | 490 | 364 | ||||||||
Excess cash | 8,144 | 41,097 | 32,934 | |||||||
Stockholders' equity | (204,842) | (174,656) | (167,968) | |||||||
Invested Capital | 251,797 | 230,286 | 206,459 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 9,960 | 9,013 | 4,987 | |||||||
Price | 17.80 75.02% | 10.17 -24.61% | 13.49 -18.34% | |||||||
Market cap | 177,283 93.41% | 91,664 36.25% | 67,276 4.63% | |||||||
EV | 181,154 | 62,333 | 35,241 | |||||||
EBITDA | (17,671) | (13,963) | (6,115) | |||||||
EV/EBITDA | ||||||||||
Interest | 752 | 427 | 8,918 | |||||||
Interest/NOPBT |